LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (OTCBB:CGRB) today announced that results from ongoing Phase II clinical trials of its investigational drug, CB7630 (abiraterone acetate) were presented at the Chemotherapy Foundation Symposium XXV, Innovative Cancer Therapy for Tomorrow, on November 9, 2007. The Chemotherapy Foundation Symposium is currently taking place in New York City.
